Aclaris Therapeutics Revenue, Profits - ACRS Annual Income Statement

Add to My Stocks
$15.43 $0.02 (0.13%) ACRS stock closing price Sep 20, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Aclaris Therapeutics stock price alone is not sufficient. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the ACRS stock is bound to reflect the impact of the YOY growth of 0. Revenue for year 2017 is $1.68M and has increased from $- year on year as is evident when you compare the latest figures in the latest Aclaris Therapeutics profit and loss statement with those of the prior corresponding period. Also see Aclaris Therapeutics assets and Aclaris Therapeutics free cash flow for a complete valuation of ACRS stock.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20172016201520142013
Aclaris Therapeutics Revenues or Net Sales
1.68M----
Cost Of Goods Sold (COGS)1.2M----
Aclaris Therapeutics Gross Profit
-----
Research & Development Expense39.79M33.47M15.33M6.5M3.48M
Selling General & Admin Expense33.1M15.09M5.32M2.02M1.76M
Income Before Depreciation Depletion Amortization-72.42M-48.56M-20.66M-8.53M-5.25M
Depreciation Depletion Amortization-----
Non Operating Income2.07M----
Interest Expense-----
Aclaris Therapeutics Pretax Income
-70.35M-48.07M-20.56M-8.51M-5.23M
Provision for Income Taxes-1.83M----
MinorityInterest-----
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-68.52M-48.07M-20.56M-8.51M-5.23M
Extraordinary Items & Discontinued Operations-----
Aclaris Therapeutics Profit/ Loss (Net Income)
-68.52M-48.07M-20.56M-8.51M-5.23M
Average Shares used to compute Diluted EPS28.1M21.42M6.11M1.72M-
Average Shares used to compute Basic EPS28.1M21.42M6.11M1.72M-
Income Before Nonrecurring Items-70.32M-48.08M-20.56M-8.52M-
Income from Nonrecurring Items1.8M----
Aclaris Therapeutics Earnings Per Share Basic Net
-2.44-2.25-3.79-6.15-
Aclaris Therapeutics Earnings Per Share Diluted Net
-2.44-2.25-3.79-6.15-
EPS Diluted Before Nonrecurring Items-2.50-2.25-3.79-6.15-
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Revance financial analysis

It is very helpful to read a report on Aclaris Therapeutics stock analysis. An investor must check the following items in an income statement:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $1.68M for this year of 2017. Our Aclaris Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. ACRS stock had a poor bottom line growth.

The income statement is also called the profit and loss statement. Apart from the ACRS income statement, one can check the Aclaris Therapeutics historical stock prices to check how the price has moved with time.

Aclaris Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
73.55
Dividend Yield
0%

Annual Income Statements - Aclaris Therapeutics Inc Industry Peers

Fibrocell Science income statement, NOVAN INC income statement, Revance income statement